Current Research Studies

Cancer – ACNS0831: Phase 3 Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years

Condition or Therapy:

Newly diagnosed ependymoma


Cancer and Blood Disorders

Study Number: ACNS0831

What is the goal of this study?

The goal of this randomized phase 3 trial is to see how well maintenance chemotherapy works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are between 1 to 21 years
  • Have been newly diagnosed with intracranial ependymoma:
    • Classic ependymoma (WHO II) or anaplastic ependymoma (WHO III), including the following subtypes: clear cell, papillary, cellular

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read more about this study at

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children's Hospital campus

Principal Investigator:

Dr. Doug Hawkins